MA53868A - Composés agonistes du récepteur bêta des hormones thyroïdiennes - Google Patents

Composés agonistes du récepteur bêta des hormones thyroïdiennes

Info

Publication number
MA53868A
MA53868A MA053868A MA53868A MA53868A MA 53868 A MA53868 A MA 53868A MA 053868 A MA053868 A MA 053868A MA 53868 A MA53868 A MA 53868A MA 53868 A MA53868 A MA 53868A
Authority
MA
Morocco
Prior art keywords
receptor agonist
thyroid hormone
beta receptor
agonist compounds
hormone beta
Prior art date
Application number
MA053868A
Other languages
English (en)
Inventor
Randall Halcomb
Thorsten A Kirschberg
F Anthony Romero
Yingzi Xu
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of MA53868A publication Critical patent/MA53868A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA053868A 2018-10-12 2019-10-10 Composés agonistes du récepteur bêta des hormones thyroïdiennes MA53868A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862745195P 2018-10-12 2018-10-12

Publications (1)

Publication Number Publication Date
MA53868A true MA53868A (fr) 2021-08-18

Family

ID=70161488

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053868A MA53868A (fr) 2018-10-12 2019-10-10 Composés agonistes du récepteur bêta des hormones thyroïdiennes

Country Status (10)

Country Link
US (2) US11203587B2 (fr)
EP (1) EP3863635A4 (fr)
JP (1) JP2022504620A (fr)
CN (1) CN112839655A (fr)
AR (1) AR116694A1 (fr)
AU (1) AU2019357618A1 (fr)
CA (1) CA3114015A1 (fr)
MA (1) MA53868A (fr)
TW (1) TWI840423B (fr)
WO (1) WO2020077123A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3965884A1 (fr) 2019-05-08 2022-03-16 Aligos Therapeutics, Inc. Modulateurs de thr-beta et leurs procédés d'utilisation
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
AU2021283577A1 (en) * 2020-06-02 2023-01-19 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone β receptor agonist
WO2022053028A1 (fr) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 Composé de 1,2,4-triazine-3,5-(2h,4h)-dicétone et son utilisation
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
PE20240097A1 (es) * 2021-03-03 2024-01-18 Terns Pharmaceuticals Inc Compuestos agonistas beta del receptor de la hormona tiroidea

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
ATE297905T1 (de) * 1999-09-30 2005-07-15 Pfizer Prod Inc 6-azauracilderivate als liganden der thyroidrezeptoren
EP1471049A4 (fr) 2002-01-30 2006-08-16 Kissei Pharmaceutical Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
AU2006271721C1 (en) * 2005-07-21 2013-09-19 F. Hoffmann-La Roche Ag Pyridazinone derivatives as thyroid hormone receptor agonists
FR2933979B1 (fr) * 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
CN102459185B (zh) 2009-04-20 2015-06-03 田边三菱制药株式会社 新型甲状腺激素β受体激动剂
WO2011038207A1 (fr) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Agonistes des récepteurs des hormones thyroïdiennes contenant du phosphore et méthodes d'utilisation
KR20140090678A (ko) * 2011-11-14 2014-07-17 세파론, 인코포레이티드 AXL 및 c-MET 키나제 억제제로서의 우라실 유도체
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
EP3189046B1 (fr) * 2014-09-05 2020-08-26 Genentech, Inc. Composés thérapeutiques et leurs utilisations
MX2019004492A (es) 2016-10-18 2019-11-18 Madrigal Pharmaceuticals Inc Metodos para tratar trastornos del higado o trastornos lipidicos con un agonista de thr-beta.
WO2019144835A1 (fr) 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 Composé de pyridazinone substitué
CN113683597A (zh) 2018-06-12 2021-11-23 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
JP2021535207A (ja) 2018-08-24 2021-12-16 ターンズ・インコーポレイテッドTerns, Inc. 甲状腺ホルモン受容体ベータアゴニスト化合物
US20210355110A1 (en) 2018-10-12 2021-11-18 InventisBio Co., Ltd. Thyroid hormone receptor agonists
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111484481A (zh) 2019-01-26 2020-08-04 察略盛医药科技(上海)有限公司 哒嗪酮类衍生物、其制备方法及其在医药上的用途
CN113474335A (zh) 2019-02-21 2021-10-01 南京瑞捷医药科技有限公司 新型化合物及其作为甲状腺激素受体激动剂的用途
CN114174282A (zh) 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用

Also Published As

Publication number Publication date
TW202027748A (zh) 2020-08-01
AU2019357618A1 (en) 2021-04-29
CA3114015A1 (fr) 2020-04-16
JP2022504620A (ja) 2022-01-13
US20220348561A1 (en) 2022-11-03
US11203587B2 (en) 2021-12-21
WO2020077123A1 (fr) 2020-04-16
EP3863635A1 (fr) 2021-08-18
TWI840423B (zh) 2024-05-01
CN112839655A (zh) 2021-05-25
US20200115362A1 (en) 2020-04-16
EP3863635A4 (fr) 2022-06-15
AR116694A1 (es) 2021-06-02

Similar Documents

Publication Publication Date Title
MA53448A (fr) Composés agonistes des récepteurs bêta des hormones thyroïdiennes
MA53868A (fr) Composés agonistes du récepteur bêta des hormones thyroïdiennes
IL282076A (en) Thyroid hormone receptor agonists
IL282666A (en) Chimeric antigen receptors specific for protein-coupled receptor g classification c group 5 individual d (gprc5d)
ZA201804997B (en) Triple glucagon/glp-1/gip receptor agonist
MA53382A (fr) Composés co-agonistes de gip/glp1
MA52642A (fr) Composés ciblant des récepteurs hormonaux nucléaires anticancéreux
EP4017875A4 (fr) Composés agonistes du récepteur bêta de l'hormone thyroïdienne
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
DK3810201T3 (da) GIP/GLP1-agonist-sammensætninger
DK3820873T3 (da) Selektive østrogenreceptornedbrydere
MA47609A (fr) Anticorps anti-il31 à usage vétérinaire
EA201791286A1 (ru) Схема дозирования для селективного агониста рецептора s1p
IL266985A (en) Agents as peptide agonists for glp1/glucagon/gip receptors
EP4028008A4 (fr) Composés agonistes du récepteur bêta de l'hormone thyroïdienne
EP4036090A4 (fr) Composé chimique en tant qu'agoniste du récepteur bêta de l'hormone thyroïdienne et son utilisation
DK3820874T3 (da) Selektive estrogenreceptornedbrydere
MA55305A (fr) Anticorps bispécifiques anti-v béta 17/anti-cd123
IL280367A (en) CD226 agonist antibodies
IL304460A (en) Estrogen receptor modulating compounds
IL280199A (en) Receptor for VISTA
GB201816639D0 (en) GLP-1 Receptor Antagonist
IL277243A (en) Inverted pyrazoles are FFA4/GPR120 receptor agonists
ZA202006157B (en) Pharmaceutical composition of kor receptor agonist
IL277859A (en) Chimeric NOTCH receptors